Targeted Genetics presents data on arthritis gene therapy

AAV delivery of gene encoding ENBREL shows promise in reducing inflammation in preclinical studies

Seattle, WA-June 5, 2000-Targeted Genetics Corporation (Nasdaq:TGEN) presented data from its gene therapy program for rheumatoid arthritis (RA) this weekend at the American Society of Gene Therapy Third Annual Meeting in Denver, Colorado. The Company is utilizing its adeno-associated virus (AAV) vector technology to deliver the DNA sequence encoding tumor necrosis factor receptor-immunoglobulin Fc fusion protein (TNFR:Fc) as a treatment for RA and other inflammatory diseases. Recombinant TNFR:Fc, ENBREL (etanercept), currently marketed for the treatment of several forms of RA, was developed by Immunex Corporation. Targeted Genetics obtained rights to the gene therapy applications of numerous genes and gene delivery technologies when it was spun out of Immunex in 1992.

Dr. Haim Burstein, Senior Scientist in the Department of Research at Targeted Genetics, presented the data in an abstract titled "Treatment of Experimental Arthritis Using Recombinant AAV-TNFR:Fc Vector Gene Therapy." The studies were conducted in collaboration with Dr. Sharon M. Wahl at the National Institute of Dental and Craniofacial Research, an institute of the National Institutes of Health. In these studies, recombinant AAV vectors containing the TNFR:Fc fusion genes were evaluated in an experimental rat model of arthritis. A single intra-articular (joint) administration of AAV-rTNFR:Fc into both rear ankle joints of arthritic rats resulted in a significant reduction of ankle and hind paw swelling as measured by arthritis index scores. A single intramuscular administration produced a similar effect. Bioactive rat TNFR:Fc protein was readily detectable in the serum of treated rats 33 days after intramuscular administration of AAV-rTNFR:Fc compared to control animals.

Injection of AAV-rTNFR:Fc into a single joint led to a reduction in hind paw swelling in the c

Contact: Page Sargisson
415-677-4455 x 229
Noonan/Russo Communications

Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted genetics presents promising data from cystic fibrosis clinical trial
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:

(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ca (PRWEB) , ... October 12, 2017 , ... ... the Surgical Wound Market with the addition of its newest module, US Hemostats ... $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
Breaking Biology Technology:
Cached News: